<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990496</url>
  </required_header>
  <id_info>
    <org_study_id>31717</org_study_id>
    <secondary_id>PSHCI #09-045</secondary_id>
    <nct_id>NCT00990496</nct_id>
  </id_info>
  <brief_title>A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)</brief_title>
  <official_title>A Phase I-II Study of Allogeneic CMV Specific Cytotoxic T Lymphocytes (CTL) for Patients With Refractory Glioblastoma Multiforme (GBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the safety and efficacy of the infusion of
      partially matched, allogeneic, CMV specific cytotoxic T cells (CTL) for patients with GBM
      that have failed primary therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tumor specimens of consenting patients will be tested by immunohistochemistry (IHC) for the
      presence of IE-1 and/or pp65. Subjects whose tumors test positive for either or both CMV
      antigens will be consented for the treatment phase which will include a regimen of
      fludarabine and cyclophosphamide daily for two days, cyclophosphamide only for a third day,
      followed by one day of rest prior to the day of CTL infusion.

      This trial intended to be a Phase 1/2 trial, but it never progressed to Phase 2 before
      termination.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Accrual goals not met
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 28, 2010</completion_date>
  <primary_completion_date type="Actual">October 28, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the incidence of tumor responses, as defined as stable disease, partial, or complete responses after the infusion of CMV CTL.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the duration and magnitude of donor chimerism post infusion by micro chimerism assays.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the incidence of increases in CMV pp65 or IE-1 T cells post infusion of allogeneic CMV CTL of GBM patients.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine safety of allogeneic CTL infusions in this patient population.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>GBM Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m2</description>
    <arm_group_label>GBM Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>600 mg/m2</description>
    <arm_group_label>GBM Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CMV Specific Cytotoxic T Lymphocytes (CTL)</intervention_name>
    <description>CTL Infusion (3 - 5 x 10E6 cells/kg)</description>
    <arm_group_label>GBM Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        FOR SCREENING

          -  Patients must have a histopathologic diagnosis of GBM.

          -  Patients from 5 to 65 years of age with GBM.

        FOR TREATMENT

          -  GBM has progressed following primary therapy.

          -  Tumor is CMV pp65 or IE1 positive by immunohistochemistry (IHC).

          -  Subjects must have pulse oximetry &gt; or = 94 % on no supplemental oxygen.

          -  Creatinine clearance must be &gt; 50 cc/min as estimated by patient's serum creatinine,
             weight, and age.

          -  Bilirubin must be &lt; 2.0 mg/dl and SGOT/SGPT &lt; 2.5 X normal.

          -  ECOG performance status must be &lt; or = 2, and for patients &lt;16 years of age, Lansky
             performance status must be &gt; or = 70%.

        Exclusion Criteria:

          -  Pregnant females

          -  Subjects who are moribund or who because of cardiac, pulmonary, renal, hepatic or
             neurologic dysfunction are not expected to survive one month following the T cell
             infusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Lucas G. Lucas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2009</study_first_submitted>
  <study_first_submitted_qc>October 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2009</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma multiforme</keyword>
  <keyword>GBM</keyword>
  <keyword>Cytomegalovirus</keyword>
  <keyword>CMV</keyword>
  <keyword>Cytotoxic T lymphocyte</keyword>
  <keyword>CTL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

